Dr. Porcu on the Need for Diverse Representation in Clinical Trials

Video

In Partnership With:

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Pierluigi Porcu, MD, professor, director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Jefferson Health, Sidney Kimmel Medical College, discusses the need for diverse representation in clinical trials.

The end goal of cancer research is to find better mechanisms for treatment delivered through more effective and safer drugs, Porcu says. The purpose of clinical trials is to test new drugs in ways that are going to be meaningful in the real world, making it important to include large, diverse populations to better replicate patient populations who are treated outside of clinical trials, Porcu explains.

However, this has been a challenge because enrollment in clinical trials features with many obstacles and barriers, leading to some trial populations to not being representative of the real world, Porcu continues. This poses challenges in determining if treatments are equally effective across different populations, Porcu concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute